Experimental Therapeutics Program

实验治疗学项目：总结 实验治疗学（ET）计划的首要使命是发现和验证 治疗目标，并随后确定，开发和测试新的治疗策略和生物标志物。 发现科学家和临床医生之间的密切合作允许多方面评估 从实验室到床边的反复循环中的治疗策略。丰富的科学发现 HDFCCC的环境导致了大量生物技术初创企业的发展， 将发现转移到私营部门用于临床实施。最常见的形式是 由加州大学旧金山分校的教师创办的早期生物技术初创企业。因此，该发现周期还可以包括“工作台”， 由于从最初的发现到临床批准和采用的漫长过程需要工业界的支持， 参与范围从早期的生物技术初创企业到制药公司。基因组和分子 成像目标验证是ET计划的中心临床焦点。有前途的临床翻译 这些策略在HDFCCC早期临床试验部门进行测试。除了促进翻译外， 从其成员的科学，ET计划作为整个HDFCCC的临床转化中心，因为 ET项目中的所有临床研究者都参加疾病特异性研究中心委员会。这些研究者 因此，作为现场委员会和 ET计划。教育技术方案的研究是在两个交叉主题下进行的： 主题1：靶向癌症信号转导 主题2：靶向表观遗传调节、细胞稳态和肿瘤环境 ET计划：关键步骤 成员（13个部门，2所学校）43 满31 协理12 与癌症有关的供资（截至2009年的直接费用） 21 511 484美元 2017年05月31日） NCI 3，071，012美元14% 同行评审$3，740，309 17% 非同行评审14，700，162美元68% 癌症相关出版物（1/2012-7/2017）672 方案间 方案内 高影响力189 28% 临床试验应计费用（2016年）237 63 治疗. 133 59 其他干预0 2 非干预性104 2

Experimental Therapeutics Program: Summary The overarching mission of the Experimental Therapeutics (ET) Program is to discover and validate therapeutic targets and subsequently identify, develop, and test novel therapeutic strategies and biomarkers. The close collaboration between discovery scientists and clinicians allows a multifaceted assessment of therapeutic strategies in iterative cycles from bench to bedside. Discoveries within the rich scientific environment of the HDFCCC have resulted in the development of a large number of biotech start-ups, and the movement of discoveries into the private sector for clinical implementation. Most often, this takes the form of early biotech start-ups launched by UCSF faculty. Thus, this discovery cycle can also include `bench to boardroom,' since the lengthy arc from initial discovery to clinical approval and adoption requires industrial participation ranging from early biotech start-ups to pharmaceutical companies. Genomic and molecular imaging target validation are a central clinical focus of the ET Program. Promising clinical translational strategies are tested in the HDFCCC Early Phase Clinical Trials Unit. In addition to facilitating translation of science from its members, the ET Program serves as a clinical translational hub for the entire HDFCCC, since all clinical investigators in the ET Program participate in disease-specific Site Committees. These investigators consequently serve as a two-way conduit of collaborative interactions between the Site Committees and the ET Program. Research in the ET Program is conducted under two cross-cutting themes: Theme 1: Targeting Signal Transduction in Cancer Theme 2: Targeting Epigenetic Modulation, Cellular Homeostasis, and the Tumor Environment ET Program: Key Metrics Membership (13 departments, 2 schools) 43 Full 31 Associate 12 Cancer-relevant Funding (direct costs as of $21,511,484 05/31/2017) NCI $3,071,012 14% Peer-reviewed $3,740,309 17% Non-peer-reviewed $14,700,162 68% Cancer-relevant Publications (1/2012-7/2017) 672 Inter-programmatic 262 39% Intra-Programmatic 150 22% High-Impact 189 28% Accruals to Clinical Trials (2016) 237 63 Therapeutic 133 59 Other Interventional 0 2 Non-interventional 104 2